Merck & Co. wins fresh EU approvals, shares supported by solid S&P 500 pharma profile

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 16:56.

Merck & Co. (US58933Y1055) sits firmly in the S&P 500 healthcare cohort as fresh regulatory decisions in Europe underpin its oncology franchise. The company’s Keytruda-based combinations have recently received further European Union approvals, according to market reports.

What recent EU decisions show

In mid-June 2026, Merck & Co. gained European Commission approval for Keytruda in combination with Padcev as a treatment option in certain bladder cancer indications, expanding its urothelial carcinoma footprint in the EU, according to recent market coverage summarized by Finanzen100. Additional reports point to approvals of Keytruda and a subcutaneous formulation in muscle-invasive bladder cancer in the European Union, broadening Merck’s oncology reach across urology segments.

These regulatory steps follow earlier European and US indications for Keytruda across lung, melanoma and other tumor types and reinforce the drug’s role as a central growth driver within Merck’s immuno-oncology portfolio, according to recent analyst commentary on large-cap pharma compiled by MarketBeat. The approvals also deepen the partnership with Astellas around Padcev in Europe’s specialist oncology centers.

Consensus and earnings outlook

Analyst data collected by MarketBeat indicate a "Moderate Buy" consensus rating on Merck & Co., with a current average price target around 128.72 US dollars per share and a market capitalization above 300 billion US dollars as of late June 2026 according to MarketBeat. The stock’s recent trading range between roughly 109 and 123 US dollars over the past 50 days places it moderately below its 52-week high near 125.14 US dollars reported earlier in 2026, data from the Financial Times show in their equity summary.

For the coming quarters, Merck’s earnings profile remains closely tied to Keytruda, Gardasil and its vaccines and animal health segment, with the next earnings date indicated around late July 2026 on several market-data platforms including TrendSpider. Dividend yields around the mid-2 percent range, combined with consistent cash generation, keep the stock in focus for income-oriented investors within the broader US large-cap pharma universe.

How Merck & Co. earns its money

Merck & Co. generates revenue primarily from prescription medicines, notably the oncology drug Keytruda, which is used in multiple cancer indications, as well as vaccines such as Gardasil for human papillomavirus and a portfolio of animal health products spanning parasiticides, vaccines and pharmaceuticals for livestock and companion animals.

Where the shares trade now

Merck & Co. shares (US58933Y1055) most actively trade on the NYSE under ticker MRK; on 2026-06-25 at 10:30 Eastern Time, MarketBeat quoted 123.80 US dollars, while Robinhood showed an intraday level around 120.00 US dollars, reflecting normal trading fluctuations in US dollars.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of an offer to buy or sell. All data are based on sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research or consult a professional advisor before making investment decisions.